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Abstract
In this study, using two different injury models in two different species, we found that early post-injury treatment with N-
Acetyl Cysteine (NAC) reversed the behavioral deficits associated with the TBI. These data suggest generalization of a
protocol similar to our recent clinical trial with NAC in blast-induced mTBI in a battlefield setting [1], to mild concussion from
blunt trauma. This study used both weight drop in mice and fluid percussion injury in rats. These were chosen to simulate
either mild or moderate traumatic brain injury (TBI). For mice, we used novel object recognition and the Y maze. For rats, we
used the Morris water maze. NAC was administered beginning 30–60 minutes after injury. Behavioral deficits due to injury
in both species were significantly reversed by NAC treatment. We thus conclude NAC produces significant behavioral
recovery after injury. Future preclinical studies are needed to define the mechanism of action, perhaps leading to more
effective therapies in man.
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Introduction
Traumatic brain injury (TBI) is a major public health issue that
affects 1.7 million Americans each year [2] and has been termed a
silent epidemic by the CDC. Many survivors experience prolonged
or even permanent neurocognitive dysfunction, with lasting
changes in cognition, motor function, and personality [3]. A
conservative estimate is that 3.2 million Americans, or 1.5% of the
population, currently live with long-term disabilities after TBI, and
these disabilities are estimated to cost $9.2 billion in lifetime
medical costs and $51.2 billion in productivity losses [4].
The pathophysiology of TBI is divided into primary and
secondary injury processes. Primary injury refers to the direct
physical trauma to the brain from impact force or penetrating
injury. Secondary injury involves a cascade of molecular
mechanisms that are initiated at the time of trauma and evolves
in the hours and days after the traumatic event. These mechanisms
include glutamatergic excitotoxicity, free-radical injury to cell
membranes, electrolyte imbalances, mitochondrial dysfunction,
inflammatory responses, apoptosis, and secondary ischemia from
vasospasm [5,6,7,8]. Since these processes are believed to be
partially responsible for the progressive neurological impairment
after TBI, the development of effective therapeutic strategies
capable of arresting secondary injury-induced damage has become
a focus of intense research activity over the last two decades, both
in clinical and preclinical settings.
N-Acetyl-L-cysteine (NAC) is the active agent in Mucomyst, a
US Food and Drug Administration approved medication with a
forty-year safety history. There is also literature on NAC as a
neuroprotective agent in preclinical models of central and
peripheral nervous injury. NAC has been shown to have
antioxidant and neurovascular-protective effects after TBI
[9,10,11]. When combined with minocycline, NAC treatment
following controlled cortical impact (CCI) increased levels of anti-
inflammatory M2 microglia in white matter tracts [12]. Such
studies however, have been primarily at the biochemical and
cellular levels, rather than focusing on behavioral parameters.
We recently conducted, in an active theatre of war, a study
demonstrating that NAC, in addition to standard symptomatic
therapy, has beneficial effects on the severity and resolution of
auditory, vestibular and cognitive function sequelae after blast
induced mild TBI (mTBI) in military personnel [1]. In this paper,
we sought to determine the efficacy of NAC in two different rodent
models of TBI to determine the generality of any effects and allow
for future mechanistic studies. The studies were organized first to
examine the efficacy of NAC in blunt trauma, to study the
potential for transitioning NAC. In order to further study this
potential, in the second group of animals, NAC was combined
with topiramate. The rationale for this is the fact that in any future
human clinical trial with NAC a standard of care for headache
could not be withheld irrespective of how the experimental
protocol is organized. Behavioral parameters of learning and
memory were used as end points to correlate with the clinical trial
of NAC in theater cited above. We used a weight drop (WD)
protocol in mice and a midline fluid percussion injury (FPI)
protocol in rats. The WD protocol models ‘‘mild’’ TBI (mTBI)
where there is little evidence for gross anatomical disruption of
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brain tissue whereas the FPI protocol simulates ‘‘moderate’’ TBI.
In the article by Hoffer [1] it was reported that NAC treatment
was supplemented, in some patients, with standard treatment with
topiramate, a non-narcotic medication used to treat post-traumatic
headache symptomatically. Hence, we added treatment with
topiramate concurrently with NAC in the mouse study of closed
head concussion.
Materials and Methods
Experiment 1: Fluid Percussion Injury in rats
Animals. Male Sprague-Dawley rats (Harlan Laboratories
Inc., Indianapolis, IN) weighing between 350 and 400 grams were
used. Animals were housed under a 12 hour light/dark cycle and
provided with food and water ad libitum. All animal procedures
were conducted in accordance with guidelines reviewed and
approved by the Institutional Animal Care and Use Committee of
Case Western Reserve University, and in accordance with the
Guide for the Care and Use of Laboratory Animals as adopted
and promulgated by the U.S. National Institutes of Health.
Fluid Percussion Injury. The fluid-percussion injury (FPI)
device used to produce experimental TBI was identical to that
described in detail by others [13]. All rats were surgically prepared
for midline FPI. The animals were randomly assigned to one of
three treatment groups: Sham (n= 9), TBI (n=9), or TBI-NAC
(n=8). Under 2% isoflurane anesthesia, a 4.8 mm diameter burr
hole was performed midline between the coronal and lambdoid
sutures, and a Luer-Loc hub was affixed to the perimeter of the
burr hole using cyanoacrylate. Dental acrylic and two small nickel-
plated screws were used to anchor a hub to the skull. Twenty-four
hours later, at the time of injury, the rats were anesthetized, the
surgical site was exposed, and the animals were connected to the
injury device. The force of the injury administered was between
1.82–1.95 atmospheres of pressure (atm) which correlates to a
moderate degree of injury. Sham animals were connected to the
injury device but no injury was delivered. NSAIDs were used for
postoperative analgesia.
Materials and Drug Treatment. NAC (Sigma Aldrich, St.
Louis MO) was dissolved in 0.9% sterile saline and the pH was
adjusted to 7.2 using hydrochloric acid. Animals assigned to TBI-
NAC received the drug at 30 minutes post-injury, injected at a
dose of 50 mg/kg intraperitoneally (ip), and then once every
24 hours over the next three days, for a total of four doses based
on previous reports [14,15]. Animals in the Sham and TBI groups
received i.p. injections with 0.9% sterile saline using the same
dosing paradigm.
Cognitive Assessment. Morris water maze - Hidden Platform.
Spatial learning and memory was assessed using the Morris water
maze (MWM) task on post injury days (PID) 10–14. The protocol
for hidden platform testing has been described in detail elsewhere
[16]. Briefly, a circular tank 180 cm in diameter, 45 cm in height,
was filled with water maintained between 25–28uC. Maze
performance and video tracking for each animal was measured
using EthoVision XT 8.5 (Noldus Information Technology Inc.,
Leesburg, VA). The goal of the task is to locate a hidden
submerged platform that is 15 cm in diameter located 2 cm below
the surface of the water. The location of the platform was fixed
across all the trials during hidden platform testing. Distinct visual
cues on the walls of the maze room, which remained constant
across all trials, provided spatial references to assist the animals in
locating the hidden platform. Rats were tested for four trials per
day over four days on PID 10–13. In each trial, the rat was placed
into the water from one of four cardinal directions in a
pseudorandom order and allowed up to 120 seconds to locate
the platform. If the animal did not locate the platform within
120 seconds, they were gently guided to it by the experimenter. All
animals were allowed to remain on the platform for 30 seconds
before being removed from the tank and placed in a heated
incubator for 10 minutes until the next trial.
Morris water maze – Probe Trial. A probe trial was performed
24 hours after the last day of hidden platform testing, on PID 14.
Each animal was allowed to swim for 30 seconds in the pool with
the platform removed to determine the number of times the
animal crossed the platform zone, defined as 26 the diameter of
the platform (i.e., 30 cm diameter, or an additional 7.5 cm radius
beyond the platform perimeter).
Morris water maze- Visible Platform. A visible platform test was
performed immediately following the probe trial, on PID 14. The
water level was lowered in the tank so that the platform surface
was 1.5 cm above water level. The animal was allowed to swim for
60 seconds in the pool to locate the platform. After the platform
was located, the animal was allowed to remain on the platform for
30 seconds. If the animal did not locate the platform within
60 seconds, it was gently guided to it by the experimenter and then
allowed to remain for 30 seconds. A second trial was immediately
conducted, and the latency to reach the platform was measured as
a test for visual acuity and swim strength.
Statistical Analysis. Statistical analyses were performed
using IBM, SPSS Statistics 20. Student’s t-test was used to
compare the duration of the suppression of the righting reflex
between the two injured groups. One-way or repeated-measures
ANOVA were used to determine overall groups differences during
MWM testing. Fisher’s LSD post hoc test was used where
appropriate. A p-value of 0.05 or less was defined as statistically
significant.
Experiment 2: Weight Drop in Mice
Animals. Male ICR mice (6–8 weeks age and 30–40 g
weight) were purchased from Harlan Sprague-Dawley (HSD
Jerusalem), Israel, and thereafter bred and raised within the
vivarium. Animals were housed 3–5 per cage with ad libitum access
to food and water on a 12 hour light/dark cycle at 2261uC. All
experimental manipulations were undertaken during the light
phase of the cycle. Experimental procedures and housing
conditions were approved by the Institutional Animal Care and
Use Committee of Tel Aviv University (M-10-030), and in
accordance with the Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by the U.S. National
Institutes of Health. A minimum number of animals were used
and all efforts were made to minimize potential suffering. Each
animal was used for only one experiment.
Weight Drop Injury. On the day of injury, mice were
randomly assigned to one of 4 treatment groups, Sham-Vehicle
(n=9), Sham-Drug (NAC + topiramate; n=6), TBI-Vehicle
(n=9), or TBI-Drug (NAC + topiramate; n=8) groups. Animals
were anesthetized lightly with isoflurane and then placed under
the weight drop device. This device consists of a cylindrical 30 g
weight with a rounded tip which is dropped through a vertical
metal guide tube (13 mm in diameter and 80 cm long). Each
mouse was placed in a right lateral decubitus position on a molded
foam pad with the right temporal region, between the corner of
the eye and the ear, directly under the guide tube. TBI was
produced by releasing the weight from the top of the tube onto the
scalp. The foam pad used to support the head of the mouse
allowed some anterior/posterior motion in the absence of any
rotational head movement [17,18]. Sham-injured mice underwent
identical treatment but no weight was dropped.
NAC and Traumatic Brain Injury
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Materials and Drug Treatment. NAC (Sigma Aldrich
Israel Ltd., Rehovot, Israel) was prepared as a suspension in
sterile 0.9% saline at a concentration of 100 mg/10 ml and pH
adjusted to 7.2. Topiramate (Sigma Aldrich Israel Ltd., Rehovot,
Israel) was prepared as a suspension in 2% dimethyl sulfoxide
(DMSO; vehicle), to provide final concentration of 30 mg/10 ml.
Both drugs were administered intraperitoneally (i.p.) in a volume
of 0.1 ml/10 g body weight. Thus, the dose after NAC was
100 mg/kg and for topiramate was 30 mg/kg. These doses were
chosen to parallel the doses used in the clinical trial in human blast
trauma [1]. One hour after injury or sham-injury, animals were
treated with single doses of either Vehicle (DMSO) or Drug (NAC
+ topiramate).
Cognitive Assessment. At 7 and 30 days after WD or sham-
injury, animals were assessed using two behavioral tests: novel
object recognition (NOR) and the Y maze.
Novel Object Recognition. An object recognition task was used to
assess recognition memory [19]. Mice were individually habitu-
ated to an open field box (59659620 cm) for 5 minutes, 24 hours
before the test. During the acquisition phase, two identical objects
(A and B), which were sufficiently heavy and high to ensure that
mice could neither move nor climb over them, were placed in a
symmetric position within the chamber. Each animal was then
placed in the box and allowed to explore the objects for 5 minutes.
Twenty-four hours after the acquisition phase, one object (A or B
randomly) was substituted for a novel one (C) and exploratory
Figure 1. MWM performance. Post injury administration of NAC significantly improves MWM performance. MWM performance as measured by
latency to reach the goal platform was compared between groups: TBI (n= 9), TBI-NAC (n= 8), and Sham (n=9). Both Sham and TBI-NAC groups have
significantly shorter latencies to reach the goal platform as compared to the TBI group. Additionally, treatment with NAC after TBI improved
performance in the MWM that reached sham levels. Data are presented as the mean6 SEM. *p,.05, ***p#.001, sham relative to TBI. { p,.05 TBI-NAC
relative to TBI.
doi:10.1371/journal.pone.0090617.g001
Figure 2. MWM platform crossing. Number of times animals crossed within a 7.5 cm radius of the platform border during the probe trial. A one-
way ANOVA showed significant differences between groups. Fisher’s LSD post hoc showed that sham and TBI-NAC had significantly better retention
of the platform location as compared to TBI alone. Data are presented as the mean 6 SEM. Brackets indicate comparisons between groups. *p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0090617.g002
NAC and Traumatic Brain Injury
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behavior was again evaluated for 5 minutes. The open field box
and all objects were thoroughly cleansed using 70% ethanol
between sessions to preclude odor recognition. Exploration of an
object was characterized as rearing on it or sniffing it at a distance
of less than 2 cm and/or touching it with the nose. Successful
recognition was revealed by preferential exploration of the novel
object [20]. Discrimination of visual novelty was assessed by a
preference index [21], determined as: (time near the new - time
near the old object)/(time near the new + time near the old object).
Y maze paradigm. The Y maze test was used to assess spatial
memory [20]. This task takes advantage of the preference of
rodents to explore novel rather than familiar places. The Y maze
was constructed of black Perspex and comprised of three arms
(8630615 cm at an angle of 120u from the others), each
distinguished by the presence of a different visual cue (triangle,
square, or circle). One arm was randomly selected as the ‘start’
arm and this remained constant for each animal on both trials.
During the initial trial, of 5 minutes duration, one of the two
remaining arms was randomly selected to be closed off whereas on
the second trial, of 2 minutes duration, both arms were open.
These trials were separated by a 2-minute inter-trial interval,
during which time the mouse was returned to its home cage and
the maze was cleaned with 70% ethanol. The time spent in each of
the arms was quantified. Discrimination of spatial novelty was
assessed by a preference index [21] determined as: (time in the
new-time in the old arm)/(time in the new + time in the old arm).
Data analysis. All results are presented as mean 6 SEM and
were analyzed with SPSS 15 software (Genius Systems, Petah
Tikva, Israel). Analysis of variance (ANOVA) was used to compare
mnemonic treatment effects between groups. Post hoc analyses
used Fisher’s LSD test. A p-value of 0.05 or less was defined as
significant statistically.
Results
Experiment 1: Fluid Percussion Injury in rats
Injury. The average injury level after FPI was 1.85 atm
(range, 1.82–1.95 atm) and suppressed the return of the righting
Figure 3. Novel Object Recognition. Preference index for the novel object in the Novel Object Recognition task across post-injury time points.
Separate ANOVAs were used to compare the preference index for the novel object during the recall phase of the task. A) Weight drop injury resulted
in significant object memory impairment on post-injury day (PID) 7 (A) and PID 30 (B) in injured vehicle-treated mice as compared to all other
treatment groups. At both post-injury time points, post-TBI treatment with N-Acetylcysteine + topiramate (Drug) was protective against injury-
induced deficits in recognition memory. Animals in the TBI-Drug group performed similarly to Sham-Vehicle and Sham-Drug groups. Values represent
the mean 6 SEM. ** p,0.01, *** p,0.001 compared to sham vehicle.
doi:10.1371/journal.pone.0090617.g003
Figure 4. Y maze preference index. Preference index for the Y maze spatial memory task on post-injury day (PID) 7 and 30. Separate ANOVAs
were used to compare the preference index for the novel arm of the Y maze during the recall trial (i.e., 2nd trial). (A) Weight drop injury resulted in
significant object memory impairment in TBI-Vehicle animals relative to the other three treatment groups on post-injury day (PID) 7. (B) On PID 30,
mice in the TBI-Vehicle group performed significantly worse as compared to the Sham-Vehicle and TBI-Drug groups (p,0.05). The Sham-Drug group
did not differ significantly from any of the other groups. N-Acetylcysteine + topiramate (Drug) was protective against injury-induced deficits in
performance in spatial memory-dependent tasks. Animals in the TBI-Drug group performed similarly to Sham-Vehicle. Values represent the mean 6
SEM. * p,0.05 compared to sham vehicle.
doi:10.1371/journal.pone.0090617.g004
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reflex an average of 449 seconds as compared with 60 seconds or
less in the sham animals. Separate t-tests were used to compare the
injury severity in atm (t=1.018, df=15, p.0.05) and righting
times (t=0.781, df=15, p.0.05) of the two injured groups and
revealed no significant difference in either outcome measure,
indicating comparable levels of injury severity.
Morris water maze. The latency to reach the goal platform
was compared across groups during hidden platform testing in the
MWM (Figure 1). A repeated measures ANOVA showed a
significant difference between treatment groups, F(2, 23) = 7.529,
p,0.01. Post hoc analysis using Fisher’s LSD test revealed that
sham animals performed significantly better during the MWM
task (i.e., shorter latency to reach the goal platform) as compared
to TBI, p=0.001. Post injury treatment with NAC significantly
improved maze performance relative to TBI, p,0.05. Perfor-
mance in the TBI-NAC group was statistically similar to sham
(p.0.05), suggesting that early administration of NAC ameliorates
these TBI-induced cognitive deficits as assessed by the MWM task,
p.0.05. A One-way ANOVA was used to compare overall
average swim speed during hidden platform testing and revealed
no significant differences between groups, F(2,23) = 1.016, p.0.05.
These data indicate that motor deficits did not contribute to the
observed group differences in latency to reach the platform.
The probe trial (PID 14) consisted of a single 30 second trial,
with the platform removed, after the final day of hidden platform
testing. The object of this test is to assess the overall learning of the
platform location. Results from the probe trial are shown in
Figure 2. The number of times each rat swam across the platform
zone, defined as an additional 7.5 cm radius around the platform,
was compared across groups. A one-way ANOVA found a
significant difference in the average number of platform crossings
between groups, F(2,23) = 7.729, p,0.01. Fisher’s LSD analysis
showed that sham and injured rats treated with NAC had
significantly more platform crossings as compared to injured
untreated rats, p#0.001 and 0.05 respectively. There was no
significant difference observed between sham and TBI-NAC
groups. The visible platform test (PID 14) was performed to assess
visual acuity, and motor ability to determine if performance
impairment was due to a deficit in visual acuity or motor ability. A
one-way ANOVA found no significant difference in the mean
latencies to reach the platform between groups.
Experiment 2: Weight Drop in Mice
Novel object recognition performance showed significant drug
treatment (F(1,26) = 4.50, p,0.05), TBI (F(1, 26) = 12.12,
p,0.01), and treatment X TBI(F(1,26) = 10.34, p,0.01) effects
in two-way repeated measures ANOVA (repeated measure: days
post-TBI). Two-way repeated measures ANOVA of Y maze
performance data showed significant effects of TBI (F(1,
25) = 4.37, p,0.05) and a TBI X drug treatment interaction
(F(1, 25) = 9.12, p,0.01). Seven days after the injury (Figs. 3A,
4A), two way ANOVA revealed main effects of TBI (F(1,
31) = 5.94, p,0.05), and a treatment X TBI (F(1,26) = 10.34,
p,0.01) interaction for novel object recognition and a TBI effect
(F(1,28) = 4.11, p = 0.05) for Y maze performance. Post-hoc
multiple range LSD tests demonstrated that mTBI mice exhibited
lower performance than the other groups in both the novel object
recognition (LSD tests p,0.01 versus the other three groups] and
the Y maze (LSD tests, p,0.05 versus the other three groups)
tasks. In contrast, the animals that were treated with topiramate
and NAC did not differ significantly from the two control (vehicle
and drug treated) groups (LSD tests). The cognitive performance
impairments persisted 30 days after the trauma (Figs. 3B, 4B); two
way ANOVA revealed main effects of TBI (F(1, 26) = 12.41,
p,0.01), treatment TBI (F(1,26) = 7.04, p,0.05) and a treatment
X TBI (F(1,26) = 7.86, p,0.01) interaction for novel object
recognition and a TBI effect (F(1,28) = 7.46, p= 0.011) for Y
maze performance. Post-hoc LSD tests showed that the TBI group
showed significant decrements in both novel object recognition
and Y maze performance, and the 30 day performance did not
differ significantly from performance at 7 days. For the novel
object recognition task, the TBI group showed poorer perfor-
mance than each of the other three groups (LSD tests, p,0.001).
For Y maze performance, the TBI group showed poorer
performance than either the control-vehicle treated (LSD test,
p,0.05) or the TBI-drug treated (LSD test, p,0.05) groups. The
drug treated control group was intermediate and did not differ
significantly from any of the other groups.
Discussion
In this study, using two different injury models in two different
rodent species, we found that early post-injury treatment with
NAC reversed the behavioral deficits associated with TBI. These
data suggest generalization of a protocol similar to our recent
clinical trial with NAC in blast-induced mTBI in a battlefield
setting [1], to mild concussion from blunt impact trauma. The use
of different models in the two rodent species are predicated on
both conceptual and technical reasons. Conceptually, the weight
drop and FPI models span the range of mild-moderate TBI.
Moreover, mice swim much more poorly than rats, and the
weights needed to injure the rat brain are an order of magnitude
greater than for mice. These larger weights frequently elicit skull
fractures.
These data augment a growing clinical and basic research
literature on the efficacy of NAC in early treatment following mild
TBI. The present study was designed to parallel a protocol used
Figure 5. Proposed mechanism of action of N-Acetylcysteine.
doi:10.1371/journal.pone.0090617.g005
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with blast mTBI in a combat setting, which included early
symptomatic treatment (e.g., topiramate for headache) and NAC.
The outcomes with both the rat fluid percussion model and the
mouse weight drop model are consistent with the neuroprotective
efficacy observed by others following a single dose of NAC in
ameliorating biochemical and histological endpoints in a rat
weight drop model [11] and of multiple doses in ameliorating
inflammatory sequelae in an open skull dural impact rat model
[9]. The antioxidant and anti-inflammatory effects of NAC
[22,23,24,25,26,27] are likely downstream consequences of
inhibition of NAC-induced nuclear factor-kB-activated pathways
that include cytokine cascades and phospholipid metabolism [28],
which may also underlie broader efficacy of NAC in rodent
ischemia-reperfusion cerebral stroke models [29,22,23,], a rodent
sensory nerve axotomy model [30], and prevention of mitochon-
drial damage with loss of dendritic spines in hippocampal neurons
[27]. Thus, NAC likely works on a number of levels - and clearly
has antioxidant activity itself. However, it also acts as a precursor
for glutathione (GSH); which is a tripeptide derived by linking the
amine group of cysteine to a glycine and to the carboxyl group of
the glutamate side-chain. GSH is an important intracellular
antioxidant, that prevents damage caused by reactive oxygen
species. GSH is synthesized within its target cells from the amino
acids, L-cysteine, L-glutamic acid and glycine. Importantly, it is
the sulfhydryl (thiol) group (SH) of cysteine that serves as a proton
donor and is thus responsible for the antioxidant activity of
glutathione. It is cysteine that is the rate-limiting factor in cellular
GSH synthesis, as this amino acid is relatively rare in foods. The
cellular bases for memory and regulation of motivation associated
with the nucleus accumbens may also be improved via NAC-
induced neuronal activation of cysteine-glutamate exchange,
augmented by indirect effects of NAC on metabolic glutamate
receptors, mGluR2/3 and mGluR5, as reported for amelioration
of cocaine-induced disruption of memory and regulation of
motivation in rodents [31]. These multiple mechanisms of NAC
actions are diagrammed in Figure 5.
The therapeutic bioavailability of systemic N-acetylcysteine
following TBI is a function of both the regulation of free levels in
the blood and permeability of the blood-brain barrier. Because
free cysteine is regulated tightly by the mammalian liver, via
mechanisms that reach a new steady-state within 24 hours [32],
repeated bolus doses are expected to be most effective for affecting
circulating free NAC levels. However, the relative impermeability
of the normal blood-brain barrier to NAC [24] implies that local
CNS bioavailability would be a natural consequence of intracra-
nial vascular disruption in mTBI, either acutely during vascular
remodeling after injury [33] or a delayed leakiness of the blood-
brain barrier from neuroinflammatory processes [33,34]. More-
over, supporting the potential role of GSH in the effects of NAC, it
has been shown that, despite its poor penetration into the CNS,
NAC can significantly elevate GSH levels in brain after oxidative
stress [35,36] and GSH deficiency [37]. Moreover, it has recently
been shown that, in a unique animal model of mTBI using
thinning of the skull and compression, that glutathione from the
periphery can enter the brain and exert neuroprotective activity
[38].
The importance of vascular damage in mTBI has been recently
emphasized by Franzblau et al [39] as a mechanistic link between
traumatic brain injury and the subsequent development of
Alzheimer’s Disease. Upregulation of the ‘‘Alzheimer’s Disease
gene set’’ after the weight drop model in mice has been recently
reported by Tweedie et al [40]. In addition, recent studies by
Acosta et al [41] suggest that neuroinflammation associated with
traumatic brain injury may suppress hippocampal neurogenesis,
with in turn, may underlie some of the cognitive deficits seen in
this disorder. The improved clinical outcomes after early NAC
treatment for blast TBI [1] are consistent with the hypothesis that
vascular effects of TBI facilitate selective delivery of NAC to
affected sites.
In summary, this paper documents the efficacy of NAC in
reversing or preventing cognitive abnormalities in rodent models
of mild to moderate TBI. Future preclinical studies are needed to
further define the mechanism of action, leading to more effective
therapies in man. We also can now begin to consider clinical work
in a human model since the current set of experiments attempted
to approximate considerations needed in a clinical study by
utilizing and accepted standard of care in the animals in
experiment two.
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